|
|
OCULAR
|
|
|
|
|
|
Any surgical intraocular treatment (including laser) within 3 months in the study eye
|
|
|
|
|
|
History of exudative AMD or Anti-Vascular Endothelial Growth Factor (anti-VEGF) injections within 6 months in the study eye
|
|
|
|
|
|
Presence of ocular media affecting visual acuity or the ability to visualize the retina in either eye (e.g., central corneal scarring, lens opacities along visual axis, posterior capsule opacification, etc.)
|
|
|
|
|
|
History of chronic, recurring inflammatory eye disease in either eye (e.g., scleritis, uveitis, corneal edema, etc.)
|
|
|
|
|
|
Presence of diabetic retinopathy in either eye
|
|
|
|
|
|
Evidence of macular edema secondary to exudation in the study eye
|
|
|
|
|
|
History of amaurosis fugax, central or retinal artery or vein occlusion, anterior ischemic optic neuropathy (AION) or non-arteritic anterior ischemic optic neuropathy (NAION) or any diagnosis of a macular disease other than AMD such as Stargardt disease, cone rod dystrophy, angioid streaks, or toxic maculopathies such as Plaquenil maculopathy
|
|
|
|
|
|
Myopia > 6.0 Diopters (D) spherical equivalent (SE) or Axial Length ≥ 26.0 mm in the study eye
|
|
|
|
|
|
Presence of visually significant epiretinal membrane in the study eye
|
|
|
|
|
|
Participation in any eye-related drug or device clinical trial involving either eye within 90 days prior to enrolling in this study and/or during study participation
|
|
|
|
|
|
Non-Ocular
|
|
|
|
|
|
Any condition that prohibits the use of intravenous contrast agents (e.g., renal insufficiency, previous anaphylactoid reaction to contrast material, treatment with nephrotoxic agents, etc.)
|
|
|
|
|
|
Previous stroke, including ischemic, hemorrhagic or transient ischemic attack (TIA)
|
|
|
|
|
|
Previous myocardial infarction (MI), including ST segment elevation (STEMI), non-ST segment elevation (NSTEMI) or coronary spasm/angina
|
|
|
|
|
|
Coronary or other intravascular percutaneous procedure, including balloon angioplasty, stent or filter placement within the last 6 months
|
|
|
|
|
|
Complete occlusion of the ophthalmic artery
|
|
|
|
|
|
Pacemaker, Cochlear, or neurostimulation implant
|
|
|
|
|
|
Presence of cranial aneurysm, clinically significant stenosis in common carotid artery or internal carotid artery, or tortuous vascular anatomy as seen on pre-procedural CT Angiogram that, in the clinical judgement of the investigator, represents an unreasonable risk to perform the intervention
|
|
|
|
|
|
Condition associated with increased bleeding risk including but not limited to: major surgical procedure or trauma within 30 days of screening; clinically significant gastrointestinal bleeding within 1 year of screening; known gastric or duodenal ulcer; history of intracranial or spinal bleeding; chronic hemorrhagic disorder; treatment with oral anticoagulant medications (e.g., Warfarin / non-vitamin K anticoagulants [NOACs] exclusionary; aspirin or clopidogrel allowed), known intracranial neoplasm, arteriovenous malformation, or aneurysm
|
|
|
|
|
|
Treatment with oral anticoagulant medications (e.g., Warfarin / non-vitamin K anticoagulants [NOACs] exclusionary; aspirin or clopidogrel allowed)
|
|
|
|
|
|
Sustained and uncontrolled hypertension with systolic blood pressure > 180 mmHg
|
|
|
|
|
|
Diagnosis of moderate to severe symptomatic congestive heart failure (CHF) or chronic obstructive pulmonary disease (COPD)
|
|
|
|
|
|
Diagnosis of connective tissue, demyelinating, autoimmune, or inflammatory diseases (e.g., lupus, rheumatoid arthritis, scleroderma, giant cell arteritis, multiple sclerosis, etc.)
|
|
|
|
|
|
Intolerance of either pre- or post- procedure medication regimen
|
|
|
|
|
|
Pregnancy, lactation, or plans to become pregnant during participation in this clinical trial
|
|
|
|
|
|
Participation in any other non-eye related drug or device clinical trial within 30 days prior to enrolling in this study and/or during study participation
|
|
|
|
|
|
Other
|
|
|
|
|
|
Use of facial fillers or paralytic drugs during study participation
|
|
|
|
|
|
Subject who, in the clinical judgement of the investigator, is not otherwise suitable for participation in the study for another clinical reason, as documented by the investigator
|
|
|
|